![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_1d5eba4b4bb57896dda18b1604bab021.svg) | Staurosporine | IC50 | 3.27 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_8edb893ba88c5700603edef201da4265.svg) | Nintedanib | IC50 | 3.0 [1], 3.2 [2], 5.0 [3], 13.0 [4] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_ac9e30b723e2c9bf1debc2a45966acbb.svg) | 3-(1H-Indol-3-yl)-4-(3,4,5-trimethoxyphenyl)pyrrole-2,5-dione | IC50 | 5.0 [1], 22.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_5888a69faa06d7673b60451157c16f76.svg) | 4-[2-[3-(2-Aminoethyl)-1-[[4-[3-(trifluoromethyl)phenyl]phenyl]methyl]indol-5-yl]oxyethyl]phenol | IC50 | 2980.0 [1], 3010.0 [2], 3080.0 [3] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_cd9f15e0c61bee3cf9b0be466db547a0.svg) | 4-[2-[[6-Amino-9-(5-phenylpentyl)-5,6,7,8-tetrahydrocarbazol-3-yl]oxy]ethyl]phenol | IC50 | 2110.0 [1], 2170.0 [2], 2190.0 [3] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_47d151d561f848592c41ab2966c047a4.svg) | Dovitinib | IC50 | 2.51 [1], 3.0 [2], 8.0 [3] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_173905a1d8206fe6271a8ee9486c99d9.svg) | Foretinib | IC50 | 2.8 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_4e38800d1c310079b3b3e65c5db78d0d.svg) | Linifanib | IC50 | 12.59 [1], 190.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_c8494007663098abb5d227cb27cc738b.svg) | Sorafenib | IC50 | 3.0 [1], 16.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_7de5848be93196a6906eba944a298431.svg) | Sunitinib | IC50 | 8.9 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_7de5848be93196a6906eba944a298431.svg) | Sunitinib | Ki | 17.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_1c0dbc70a65a3eccf3e39ecce75f7f37.svg) | Pazopanib | IC50 | 46.0 [1], 47.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_9d111ca31c6b5557bbe95cc7cad92c76.svg) | Vatalanib | IC50 | 195.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_8a69b3902a36c5bcb114db8f49f8eabe.svg) | Semaxanib | IC50 | 50.0 [1], 500.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_ae3c621c3ca0049e7a4045efa2e650e7.svg) | Tivozanib | IC50 | 0.24 [1], 3.11 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_aa4ae66a17e1730306dedb6ebaeee891.svg) | 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide | IC50 | 18.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_f1099aa3bd39876799914a83803e440e.svg) | Tak-593 | IC50 | 1.1 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_bbb936490cb2d36df2f50d54114bf2ad.svg) | 1-[4-(4-Aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-3-(3-methylphenyl)urea | IC50 | 13.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_9d38a171c31a3d0ddba7416e6ed4a947.svg) | (1S)-2-(1H-Indol-3-YL)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-YL}oxy)methyl]ethylamine | IC50 | 50000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_c7ac197ab864d234059c44c850b134e9.svg) | 9-(2,6-Dimethylstyryl)-N-(4-(dimethylphosphoryl)phenyl)-9H-purin-6-amine | IC50 | 151.0 [1], 1000.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_a40f7fd3fe79eff4088f398fada20283.svg) | 2-[2-[2-[5-Chloro-2-[[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]ethyl]phenyl]propanamide | IC50 | 9.0 [1], 52.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_714080dc4d2f810baad846bc85d1bb9a.svg) | 2-[2-[2-[5-Chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]ethyl]phenyl]-2-methylpropanamide | IC50 | 3.0 [1], 23.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_c6ef62e9109dfa8720ded153ca24f174.svg) | 2-(2-(2-(5-Methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)ethyl)phenyl)propanamide | IC50 | 15.0 [1], 526.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_0e7e824cdcc7cb242264c5e9c78de8bb.svg) | 2-[2-[2-[2-[(1-Piperidin-4-ylpyrazol-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]propanamide | IC50 | 27.0 [1], 68.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_b56225cd7f2c5ec8c8a31125f6d7889f.svg) | 2-[2-[2-[2-[[1-(1-Methylpiperidin-4-yl)pyrazol-4-yl]amino]-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]propanamide | IC50 | 27.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_7936547b28f2fb478df5eea8ffe02669.svg) | 1-[2-[2-[2-[(6-Methoxypyridin-3-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 8.0 [1], 394.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_705af426f568c65619103ffb19ec00f5.svg) | 2-[2-[2-[2-(4-Piperidin-4-ylanilino)-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]butanamide | IC50 | 91.0 [1], 173.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_f7efb66e46f617e3816244a5f5bbabd5.svg) | 1-[2-[2-[2-(4-Piperidin-4-ylanilino)-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 10.0 [1], 26.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_5b47ca09d1b6c7917faceae1b3934750.svg) | 1-[2-[2-[2-[4-(1-Methylpiperidin-4-yl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 9.0 [1], 27.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_097643d4e8aff6458257ad7e6d5d2ed7.svg) | 1-[2-[2-[2-[4-(Azetidin-3-yl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 22.0 [1], 38.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_fe88d963f5cfa8be6241518d3afc9f79.svg) | 1-[2-[2-[2-[(6-Piperidin-4-ylpyridin-3-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 28.0 [1], 51.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_ddb1698639302076cfcc7c0c0e3a32af.svg) | 1-(2-(2-(5-Chloro-2-(pyridin-3-ylamino)pyrimidin-4-yl)ethyl)phenyl)cyclopropanecarboxamide | IC50 | 8.0 [1], 17.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_f74cfb9f15f975e7d1a37095c5d716e9.svg) | 1-[2-[2-[5-Chloro-2-[4-(1-methylpiperidin-4-yl)anilino]pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 10.0 [1], 19.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_988e01b2a3ba2b6bda7342b734aeee85.svg) | 1-[2-[2-[5-Chloro-2-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 75.0 [1], 92.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_61a9e7cd66b0eb51186d832111f6b077.svg) | 1-(2-(2-(5-Chloro-2-(pyrimidin-5-ylamino)pyrimidin-4-yl)ethyl)phenyl)cyclopropanecarboxamide | IC50 | 39.0 [1], 267.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_34451e5b6d62d5cbec8416852d6218e6.svg) | 1-[2-[2-[5-Chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 4.0 [1], 9.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_a6d433d838358dd3236e8da5bcad37a8.svg) | 1-[2-[2-[2-[[1-(Azetidin-3-yl)pyrazol-4-yl]amino]-5-chloropyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 6.0 [1], 30.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_7e9321df5c0b5ef7f9f71c69efb8832b.svg) | 1-[2-[2-[5-Chloro-2-[(6-piperidin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 11.0 [1], 51.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_fc06b155987278da9b0a3de80cf58018.svg) | 1-[2-[2-[5-Chloro-2-[(1-piperidin-4-ylpyrazol-4-yl)amino]pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 9.0 [1], 62.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_7ef27cae87364a0826859c6e2a427e31.svg) | 1-[2-[2-[5-Chloro-2-[[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 3.0 [1], 5.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_cf61edb9eab1542e9265dbf9d10a6d38.svg) | 1-(2-(2-(2-(1H-Pyrazol-4-ylamino)-5-chloropyrimidin-4-yl)ethyl)phenyl)cyclopropanecarboxamide | IC50 | 3.0 [1], 11.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_0737f0f3b5de7656c7c60e8cbd8e879a.svg) | 1-[2-[2-[5-Chloro-2-[(1-pyrrolidin-3-ylpyrazol-4-yl)amino]pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 7.0 [1], 38.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_611d99360a4424885d08541dc9360dac.svg) | 1-[2-[2-[5-Chloro-2-[[1-(1-methylpyrrolidin-3-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 7.0 [1], 14.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_412798413f63edf2cfcf07d7d33a58f2.svg) | Tert-butyl N-[1-[4-[[4-[2-[2-(1-carbamoylcyclopropyl)phenyl]ethyl]-5-chloropyrimidin-2-yl]amino]phenyl]ethyl]carbamate | IC50 | 2.0 [1], 25.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_d0b1548db4d985c1d173411988989925.svg) | 2-(2-(2-(2-(1H-Pyrazol-4-ylamino)-5-chloropyrimidin-4-yl)ethyl)phenyl)propanamide | IC50 | 9.0 [1], 64.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_4a36b2829df8794927c16f841b8b5ccc.svg) | 2-(2-(5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)pyrimidin-4-ylethyl)phenyl)propanamide | IC50 | 16.0 [1], 76.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_ac0f63491de1549ee058121eb212de0e.svg) | 1-[2-[2-[5-Chloro-2-(4-piperidin-4-ylanilino)pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 10.0 [1], 38.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_bc4dbbad3628ae30de7cba772502a0c1.svg) | (2R)-2-[2-[2-[2-(4-Piperidin-4-ylanilino)-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]butanamide | IC50 | 103.0 [1], 329.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_3cb58056c02f9023e761401ac5f908fa.svg) | (2S)-2-[2-[2-[2-(4-Piperidin-4-ylanilino)-5-(trifluoromethyl)pyrimidin-4-yl]ethyl]phenyl]butanamide | IC50 | 75.0 [1], 315.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_60cae61b79d5a937d18583ff8f537563.svg) | 1-[2-[2-[5-Chloro-2-[[6-(1-methylpiperidin-4-yl)pyridin-3-yl]amino]pyrimidin-4-yl]ethyl]phenyl]cyclopropane-1-carboxamide | IC50 | 1.0 [1], 4.0 [2] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_9b0846c6235f0aecda0470a6e161c35a.svg) | Ellagic acid | IC50 | 1540.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_7c1f47f3c7bae38fb065c983ece631c1.svg) | Vandetanib | IC50 | 233.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_e1bd3c1d60717a09fae0532edc016b5c.svg) | Axitinib | IC50 | 0.1 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_12fa190f2d2e4b2561e24185e6a9c597.svg) | Nintedanib esylate | IC50 | 13.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_fb653bf3974ba8878f0badcb4c717a18.svg) | Cediranib | IC50 | 3.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_16035fc8c63bed578e37056a164d7b84.svg) | Lenvatinib | IC50 | 5.2 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_86afa169fbf5024375ee5d399dedddf5.svg) | Saracatinib | IC50 | 10000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_0a83b01cf93719a90ccaeda771089c43.svg) | Doramapimod | IC50 | 270.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_6ce223fbd5241efea172edc836e9b6c1.svg) | Sotrastaurin | IC50 | 4600.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_c92f4bc6d141b8aeb107ab58dde46ce7.svg) | Motesanib | IC50 | 6.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_308f46b4c40c812c872cfe130b3fc720.svg) | 3,9-Bis((ethylthio)methyl)-K-252a | IC50 | 39.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_aea8e5cd5eedd851a20871e2fe5ff0da.svg) | Danusertib | IC50 | 161.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_94feb385cecaa610e1d68d9fb9d55ef3.svg) | Pyridone 6 | IC50 | 690.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_2adbc4a307d22bed17e0f710542542e9.svg) | Entrectinib | IC50 | 1000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_7c73239bc31d4875fd802deba6fd37c5.svg) | Filgotinib | IC50 | 274.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_fa37ae125bcd4e6df1af4be57fbea491.svg) | 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea | IC50 | 1.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_6b2c7526f6a3e2051074ade188c47877.svg) | Telatinib | IC50 | 4.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_6eb85432df5d02aab0b18480749b4c05.svg) | 5-(5,6-Dimethoxy-1-benzimidazolyl)-3-[[2-(trifluoromethyl)phenyl]methoxy]-2-thiophenecarboxamide | IC50 | 92.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_8fc6ee09adb3fcc99c67a2a384c17924.svg) | 2-(Pyridin-4-yl)-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-one | IC50 | 10000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_3b9e10412a2d6240147321cb2601cee1.svg) | VEGF receptor tyrosine kinase inhibitor III | IC50 | 125.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_495c00c0eebcec0612a883578e83da0a.svg) | Milciclib | IC50 | 920.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_899e7233470c1e6b0c695ac9e914d9bb.svg) | 3-[4-[4-[2-[3-[(Dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-ethylpyrazol-3-yl]phenyl]-1,1-dimethylurea | IC50 | 74.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_ad2e213c6bc5eb972596bba5a265d460.svg) | 1-(3-Chlorophenyl)-3-{5-[2-(Thieno[3,2-D]pyrimidin-4-Ylamino)ethyl]-1,3-Thiazol-2-Yl}urea | IC50 | 14.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_c03f7d5f41fab476c99fd46f75d44073.svg) | Pha-793887 | IC50 | 10000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_2f15fb478c8045b6bf5d450f1eb5924b.svg) | Lucitanib | IC50 | 10.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_b63a2565bd4d512206a1c9679cacee61.svg) | 3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide | IC50 | 54.2 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_179888a64edb35ddee0be2a16e245b3a.svg) | MK-2461 | IC50 | 78.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_f4b83a1425a555dfbf43ceee061e62b1.svg) | Serotonin hydrochloride | IC50 | 50000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_afa447a225ad64d0a8c174060b5255d8.svg) | Cc-223 | IC50 | 651.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_3bdf7128b3bf4b644abdbc0d5a4f70a1.svg) | N-(3-Chloro-4-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine | IC50 | 2400.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_fe739739798d5a426922dc4c74a41375.svg) | (4S,6Z,9S,10S)-9,10,18-Trihydroxy-16-methoxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,15,17-tetraene-2,8-dione | IC50 | 1.13 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_478f8c74275fce83224a96edad0f0b1f.svg) | JNK Inhibitor VIII | Ki | 7100.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_9ac8c17a1cd78f944fc3ce79f16d4238.svg) | Nms-P937 (nms1286937) | IC50 | 10000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_a97274caafef70d6423d3784397e9e54.svg) | Pyrimidone, 22 | IC50 | 120.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_229be97168f5a1e19a21ea31c162ddf6.svg) | 3-(4-{4-Aminofuro[2,3-d]pyrimidin-5-yl}phenyl)-1-[2-fluoro-5-(trifluoromethyl)phenyl]urea | IC50 | 7.59 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_64f69317c84e5d1efc4211ef1e986fd2.svg) | 2-(4-Fluoroanilino)-5-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-3-methylpyrimidin-4-one | IC50 | 5.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_3ee7568a09840225cd8af9a1f5126d5a.svg) | Tafetinib | IC50 | 1.3 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_9e568937b6b0bebb88ee373914e98c35.svg) | 3-(3-Hydroxypropyl)-7-(propan-2-yloxymethyl)-3,13-diazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1(16),2(10),4(9),5,7,11(15),17,19,21-nonaen-14-one | IC50 | 4.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_c33668b892afbb36d843e9dd0815b38f.svg) | 5-[2,4-Dihydroxy-6-(4-Nitrophenoxy)phenyl]-N-(1-Methylpiperidin-4-Yl)-1,2-Oxazole-3-Carboxamide | IC50 | 10.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_e22ac69177233700795632410f872632.svg) | (12E,25E,28E)-5,16,21,32-Tetrabromo-4,20-dihydroxy-12,25-bis(hydroxyimino)-2,18-dioxa-10,27-diazapentacyclo[28.2.2.214,17.13,7.119,23]octatriaconta-1(32),3,5,7(38),14,16,19,21,23(35),28,30,33,36-tridecaene-11,26-dione | IC50 | 3200.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_7ba2c79d04a961439347046220210c11.svg) | 2-(4-((6,7-Dimethoxyquinazolin-4-yl)oxy)phenyl)-N-(1-isopropyl-1H-pyrazol-4-yl)acetamide | IC50 | 8.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_c5022113a7c4da69b9d4bc132325dd30.svg) | Alsterpaullone, 2-Cyanoethyl | IC50 | 1000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_969493da19549693a0acb94f703a8630.svg) | N-(4-Chlorophenyl)-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide | IC50 | 2.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_801b71b496c9e614d27c57f59ce0b9c5.svg) | (1S,2S,3R,4R)-3-[[5-Chloro-2-[[(7S)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide | IC50 | 48.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_dd39a95211e2a7beed01f0aa58e3406a.svg) | Flt3-IN-1 | IC50 | 3700.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_37db551c0860118de4481a6c244df05d.svg) | (2S)-1-(1H-Indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-yl)oxy-propan-2-amine | IC50 | 50000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_f8dea142aa4a3f574f20a24329144dbd.svg) | CID 118295624 | IC50 | 410.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_5f9d90b38bf8a433ad98aef5d1ac5970.svg) | Unii-BL7xsd8R7B | IC50 | 360.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_b800922b5c769ca9c52161d0b5a33c4a.svg) | 8-[2-Methoxy-5-(4-methylpiperazin-1-yl)anilino]-1-methyl-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide | IC50 | 587.0 [1] |
![](https://images.aatbio.com/dataset/ic50/vascular-endothelial-growth-factor-receptor-3_8dd9e09809fda3f168eb4b9ad40384a9.svg) | N-(3-Cyclopropyl-1H-pyrazol-5-YL)-2-(2-naphthyl)acetamide | IC50 | 10000.0 [1] |